PATENT CLAIM ANALYSIS

Application Number: 15775080
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "04400A"]

Abstract:
Provided is a composition containing an agent capable of inhibiting the expression of HMGCLL1 IS3, and a method for treating or preventing a malignant tumor. The malignant tumor expresses HMGCLL1 IS3. The malignant tumors may show resistance to tyrosine kinase inhibitors. A method, composition, and kit for determining the expression level of HMGCLL1 IS3, for diagnosing drug resistance, for determining the probability of developing a malignant tumor, and for predicting prognosis of malignant tumors are provided.

Claim (Index 12):
The method of  claim 10 , wherein the solid cancer is selected from the group consisting of neuroblastoma, adenocarcinoma, osteosarcoma, breast invasive ductal carcinoma, glioblastoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, malignant melanoma, embryonal rhabdomyosarcoma, gastric adenocarcinoma, bladder carcinoma, and a combination thereof.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 93.0
- Lexical Diversity: 1.86957
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12708294', '13050604', '14979566', '11317516', '13809880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8164206566359844
- 35 USC 102 Novelty (BERT): 0.5042212464753166
- Combined Prediction Score: 0.7852007156199177
- Mean Citation Score: 232.853344
- Max Citation Score: 236.59807
- Similarity Product: 146.24211025178374

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test